What is NR?
NR (nicotinamide riboside) is a naturally occurring form of vitamin B3 and one of the two leading oral NAD+ precursors, alongside NMN. It was identified as an NAD+ precursor in a landmark 2004 paper by Charles Brenner at Dartmouth, which predates much of the recent NMN research and is part of why NR has accumulated the largest body of published human trial data of any NAD+ precursor — it’s been commercialized longer, primarily through ChromaDex’s Tru Niagen brand and Elysium Health’s Basis.
The core pitch for both NR and NMN is the same: NAD+ levels decline with age, and NAD+ is required for hundreds of cellular processes including energy metabolism, DNA repair, and sirtuin activity. Where NR and NMN differ is in their conversion pathway — NR must first be converted to NMN by NRK (nicotinamide riboside kinase) enzymes before that NMN is converted to NAD+, one additional step compared to NMN’s more direct route.
Despite that extra conversion step, NR was the first of the two precursors to demonstrate reliable NAD+ elevation in human trials, and its trial portfolio includes findings specific to cardiovascular health — including reduced arterial stiffness and blood pressure in older adults — that don’t yet have direct NMN equivalents. This has made the “NR vs. NMN” comparison less about which is mechanistically superior and more about which outcomes each has the strongest evidence for.
For a broader view of the NAD+ precursor landscape — including direct NAD+ supplementation and IV NAD+ — see the class overview, which covers how all of these approaches relate to the same underlying goal of raising cellular NAD+ availability.
How it works
NR → NMN → NAD+ Pathway
After absorption, NR is phosphorylated by NRK1 or NRK2 (nicotinamide riboside kinases) to form NMN, which is then converted to NAD+ by NMNAT enzymes — the same final step shared with direct NMN supplementation. This two-step conversion (NR → NMN → NAD+) is the basis for the “NR is one step further from NAD+” framing, though in practice this hasn’t been shown to meaningfully limit NR’s ability to raise blood NAD+ levels, which multiple trials have confirmed it does.
NAD+ Downstream Effects — Identical to NMN
Once NR has been converted to NAD+, the downstream biology is identical to any other NAD+ precursor — NAD+ serves as a required cofactor for sirtuins (implicated in cellular stress response and lifespan regulation in animal models), PARPs (DNA damage repair enzymes), and is consumed by CD38 (an NAD+-degrading enzyme that increases with age). Because the downstream effects converge regardless of which precursor is used, differences between NR and NMN in human outcomes likely come down to absorption, conversion efficiency, and dosing — areas where head-to-head data remains limited.
Cardiovascular-Specific Effects
NR’s most distinctive trial findings are cardiovascular: a 2018 trial found NR supplementation reduced arterial stiffness and systolic blood pressure in older adults with mildly elevated baseline blood pressure, and other research has examined NR’s effects in conditions like heart failure. The proposed mechanism involves NAD+’s role in mitochondrial function within vascular tissue and its influence on nitric oxide signaling, though the precise pathway connecting NAD+ restoration to improved arterial stiffness is still being characterized. This cardiovascular angle is one of NR’s more differentiated areas of evidence relative to NMN.
What the research shows
What the community reports
NR has a long track record in the supplement community, partly because it’s been commercially available (as Tru Niagen and Basis) for longer than most NMN products, giving people more time to form opinions on it.
Common misconceptions
"NR is less effective than NMN because it's one step further from NAD+."
The extra NRK-mediated conversion step is mechanistically real, but NR was the first precursor shown to reliably raise blood NAD+ in humans, and it has the largest published human RCT base of any NAD+ precursor. No head-to-head trial has shown NMN outperforming NR on NAD+ elevation or any clinical outcome. The 'one step further' argument is a hypothesis, not a demonstrated practical disadvantage.
"NR is just vitamin B3, so any B3 supplement would do the same thing."
NR is part of the vitamin B3 family, but it has distinct pharmacokinetics from niacin or standard nicotinamide — it raises blood NAD+ more effectively at studied doses and doesn't cause the flushing reaction associated with niacin. The specific trial evidence (NAD+ elevation, arterial stiffness reduction) exists for NR at specific doses, not for generic B3 supplementation broadly.
"The Martens 2018 trial proves NR prevents heart disease."
That trial found NR reduced arterial stiffness and systolic blood pressure over six weeks in healthy older adults — real and meaningful findings, but a six-week surrogate-marker study is a long way from demonstrating reduced heart disease incidence or cardiovascular events. Arterial stiffness and blood pressure are associated with cardiovascular risk, but improving them in a short trial isn't the same as proving a reduction in heart attacks, strokes, or mortality.
Open PepperLedger to track your NR protocol →
Free to join. No credit card. Ask the Coach about NR dosing, timing, and NAD+ precursor comparisons.
Free to join · No credit card · 23-day Pro trial included